Pancreatic Cancer Drug Pipeline Beyond KRAS — PatSnap Eureka
Pancreatic Cancer Drug Pipeline Beyond KRAS: TME, Stromal Targeting & Combinations
PDAC's desmoplastic tumor microenvironment drives chemoresistance and immunosuppression well beyond KRAS. Discover the emerging therapeutic strategies—from anti-GREM1 stromal antagonists to EZH2 epigenetic remodeling—shaping the next frontier in pancreatic cancer drug development.
Two Interacting Pathological Layers Drive PDAC Resistance
Pancreatic ductal adenocarcinoma (PDAC) is shaped by two interacting pathological architectures: a high-frequency oncogenic driver layer (KRAS mutations present in the vast majority of cases) and a dense desmoplastic tumor microenvironment (TME) composed of cancer-associated fibroblasts (CAFs), tumor-associated macrophages (TAMs), extracellular matrix proteins, and immunosuppressive cytokines. The interplay between these layers—not KRAS alone—determines therapy resistance and patient outcome.
According to the National Cancer Institute, pancreatic cancer remains one of the most lethal solid tumors. Patent and literature analysis via PatSnap Eureka reveals that emerging strategies increasingly target the stroma and immune contexture rather than KRAS alone. PatSnap's life sciences intelligence platform provides deep visibility into this rapidly evolving IP landscape.
Key actionable nodes identified in the retrieved dataset include: CSF1R (TAM survival and function), GREM1 (stromal chemoresistance driver), EZH2 (epigenetic suppressor of innate immune activation), EGFR (wild-type KRAS subpopulation target), and a constellation of co-dependency targets including MEK, CDK4/6, IL-33, CCR1, CD47/SIRPα, SOS1, and JNK1. The World Intellectual Property Organization database reflects a surge in multi-target PDAC combination filings from 2020 onward.
Eight Emerging Strategies Targeting the PDAC TME and Stroma
From anti-GREM1 stromal antagonists to nucleic acid modalities, the patent landscape reveals a multi-modal assault on PDAC's resistance architecture—extending well beyond KRAS inhibition.
Anti-GREM1 Antagonists + Chemotherapy or MEK Inhibitors
UCB Biopharma SRL holds the largest coherent stromal-targeting patent cluster in the dataset (7+ filings, WO/US/CA/AU/BR). Anti-GREM1 combined with gemcitabine demonstrates significantly improved survival vs. vehicle controls in KPC mouse models. A compensatory MEK-ERK pathway upregulation following GREM1 blockade motivates additional MEK inhibitor combination claims targeting KRAS G12D and G12R mutations. Evidence is preclinical (KPC mouse model).
UCB Biopharma · 2023–2025 · KPC preclinicalAnti-CSF1R (Cabiralizumab) × Anti-PD-1 (Nivolumab)
Bristol-Myers Squibb holds a multi-jurisdictional portfolio (WO, US, CA, AU, SG, IL) claiming cabiralizumab + nivolumab for locally advanced, metastatic, and MSS PDAC. CSF1R blockade depletes TAMs and upregulates PD-L1, creating pharmacodynamic synergy with PD-1 blockade. The US patent explicitly references clinical trial NCT02526017—the most advanced clinical translation signal in this dataset.
Bristol-Myers Squibb · NCT02526017 referenced · US patent active 2021EZH2 Inhibition + MEK + CDK4/6 Triple Combination
A University of Massachusetts patent (WO, 2023) claims a triple combination of PRC2 inhibitor + MEK inhibitor + CDK4/6 inhibitor for KRAS-mutant PDAC. EZH2 inhibition unleashes CCL2, CXCL9/10 chemokines and upregulates MHC-I and NK ligand expression, converting an immunologically cold tumor to an inflamed phenotype. This epigenetic immunological switch is a PDAC-specific mechanism distinct from lung adenocarcinoma.
University of Massachusetts · WO 2023 · PDAC-specific mechanismMEK + CDK4/6 Inhibition (Trametinib + Palbociclib)
MSKCC filed a WO patent claiming trametinib + palbociclib for KRAS-mutant PDAC with PDX and EPO-GEMM model evidence. Separately, Genentech (IL, MX) combines cobimetinib (MEK inhibitor) with ponatinib to co-target PDGFRα, S6, and STAT3—addressing adaptive resistance whereby MEK inhibition alone induces compensatory activation of these nodes. Both strategies reflect a resistance pre-emption design principle.
MSKCC + Genentech · PDX/GEMM evidence · MEK resistance addressedIL-33/ILC2 Axis Activation + PD-1 Inhibition
MSKCC patents describe IL-33 administration (alone or with PD-1/PD-L1 inhibitors) to activate ILC2-dependent pancreatic tissue-specific T cell immunity. Preclinical data report >70% cure rates in mouse models and ~40% reduction in tumor volume with rIL33 + anti-PD-1 in PD-1-resistant models. A second MSKCC series targets Type 2 cytokine signaling in KRAS-mutant (G12C, G12D, G12V) and TP53-comutant PDAC.
MSKCC · >70% cure rates preclinical · PD-1-resistant modelsCCR1 Antagonism (BX-471) + Standard-of-Care Combinations
Cambridge Enterprise Limited (CN filing, 2022) claims CCR1 antagonists for PDAC, with evidence that high macrophage infiltration correlates with poor prognosis. CCR1 antagonism disrupts macrophage-mediated pro-invasive signaling. Combinations with gemcitabine, 5-FU, FOLFIRINOX, nab-paclitaxel, and immune checkpoint inhibitors are claimed—making CCR1 a versatile combination partner across the standard-of-care backbone.
Cambridge Enterprise · 2022 CN filing · BX-471 exemplifiedAptamer-Linked ASOs Targeting KRAS mRNA, SOS1, SOS2
American Microjet Technology LLC (CN, 2025) describes aptamer (P19)-linked antisense oligonucleotides targeting KRAS mRNA, SOS1, and SOS2 transcripts in PDAC cells. The aptamer directs the conjugate to pancreatic cancer cells, targeting the RTK-RAS-ERK cascade at the RNA level—extending beyond small-molecule KRAS inhibition. Earlier precedent from Columbia University describes MDA-7 (IL-24) gene delivery combined with KRAS antisense silencing for synergistic apoptosis.
American Microjet · CN 2025 · RNA-level KRAS targetingEGFR Targeting (Nimotuzumab) in Wild-Type KRAS PDAC
Innocimab Pte Ltd (Singapore) holds the most geographically distributed single-antibody patent family in the dataset (WO, EP, AU, CA, KR, SG, IN, US, MY), claiming nimotuzumab for PDAC patients with wild-type KRAS, HRAS, or NRAS. Multiple jurisdictions reference Schultheis et al. (Ann Oncol 2017) showing clinical benefit with nimotuzumab + gemcitabine in wild-type KRAS patients—retrospective clinical evidence embedded in patent text.
Innocimab · 8+ jurisdictions · Schultheis Ann Oncol 2017 clinical evidenceVisualising the PDAC Beyond-KRAS Patent Landscape
Patent activity and translational readiness across key non-KRAS targets and combination strategies, derived from PatSnap Eureka analysis of retrieved patent and literature records.
Patent Filing Activity by Key Assignee (Non-KRAS PDAC)
UCB Biopharma and Bristol-Myers Squibb lead patent activity in stromal and immune TME targeting respectively, with MSKCC as the most active academic assignee.
Translational Readiness: PDAC Combination Strategies
CSF1R × PD-1 is the only strategy with explicit clinical trial reference (NCT02526017); most TME-directed approaches remain preclinical-stage as of this dataset snapshot.
Seven Combination Paradigms Shaping PDAC Drug Development
Retrieved patent data reveal convergent multi-modal strategies targeting PDAC's layered resistance architecture, from stroma-first sensitization to innate immune re-activation.
Stromal Priming + Chemotherapy Backbone
UCB Biopharma's anti-GREM1 + gemcitabine data support a "stroma-first" sensitization paradigm. Stromal GREM1 confers chemoresistance; its removal restores tumor cell sensitivity to cytotoxic agents. Evidence from KPC mouse models demonstrates significantly improved survival vs. vehicle controls.
TAM Depletion + Checkpoint Blockade
The CSF1R × PD-1 combination reflects the hypothesis that TAM-mediated immunosuppression is the primary barrier to checkpoint efficacy in PDAC. Cabiralizumab upregulates PD-L1, creating a pharmacodynamic rationale for concurrent anti-PD-1 therapy. Referenced clinical trial NCT02526017 is the most advanced signal in this dataset.
Senescence Induction + Epigenetic De-repression + Immunotherapy
The University of Massachusetts EZH2 patent proposes a three-way combination (PRC2 inhibitor + MEK inhibitor + CDK4/6 inhibitor) that converts PDAC from immunologically cold to inflamed by unleashing SASP-driven chemokines and MHC-I upregulation—compatible with subsequent checkpoint or adoptive cell therapy.
KRAS Inhibitor + Innate Immune Activation (CD47 Blockade)
I-Mab Biopharma's patent signals a myeloid-arm strategy: CD47/SIRPα disruption stimulates macrophage phagocytosis of KRAS-mutant tumor cells while KRAS inhibition increases tumor vulnerability. This approach re-purposes macrophages as effectors rather than suppressive bystanders.
Key Patent Assignees and Their PDAC TME Strategies
Commercial activity is driven by a small group of biopharma firms; academic institutions contribute complementary mechanistic and biomarker-focused IP. Data from PatSnap Analytics and EPO patent records.
| Assignee | Primary Target / Strategy | Jurisdictions | Translational Stage | Key Claim |
|---|---|---|---|---|
| UCB Biopharma SRL | Anti-GREM1 + gemcitabine / MEK inhibitors | WO, US, CA, AU, CN, BR | Preclinical (KPC) | Stromal GREM1 drives chemoresistance; blockade restores sensitivity |
| Bristol-Myers Squibb | Cabiralizumab (CSF1R) + Nivolumab (PD-1) | WO, US, CA, AU, SG, IL | Clinical (NCT02526017) | TAM depletion potentiates anti-PD-1 in MSS PDAC |
| Memorial Sloan Kettering | MEK+CDK4/6; IL-33/ILC2; Type 2 cytokine inhibition | WO, US, IL | Preclinical (PDX/GEMM) | Broadest academic TME-immune remodeling IP portfolio |
| Genentech, Inc. | MEK+PDGFRα/STAT3 (cobimetinib+ponatinib); TIGIT+PD-L1+chemo | IL, MX, WO | Late preclinical / IND | MEK resistance pre-emption + dual checkpoint + chemotherapy |
| Innocimab Pte Ltd | Nimotuzumab (anti-EGFR) for wild-type KRAS PDAC | WO, EP, AU, CA, KR, SG, IN, US, MY | Clinical evidence (Schultheis 2017) | Precision stratification: wild-type KRAS/HRAS/NRAS subpopulation |
Clinical & Translational Signals in the Dataset
Track Every PDAC Clinical Signal in Real Time
PatSnap Eureka monitors patent filings, clinical trial references, and literature across 150M+ documents for instant pipeline intelligence.
What the PDAC Beyond-KRAS Patent Landscape Means for Drug Developers
Stromal targeting is the most patent-active non-KRAS frontier in this dataset. UCB Biopharma's GREM1 program and Cambridge Enterprise's CCR1 data both support the hypothesis that stroma-mediated chemoresistance is a tractable therapeutic node. Organizations developing GREM1, CCR1, FAK, or related stromal targets should monitor biomarker (GREM1 expression level) patient selection strategies identified in these filings. PatSnap's chemistry and materials intelligence tools support biomarker-driven target identification.
TAM depletion + PD-1 blockade has the most advanced clinical translation signal. The Bristol-Myers Squibb CSF1R × PD-1 program is the only strategy in this dataset with explicit clinical trial data referenced (NCT02526017). PDAC drug developers should assess whether CSF1R blockade as monotherapy or in triplet combinations with chemotherapy offers incremental benefit beyond the doublet. NIH ClinicalTrials.gov tracks ongoing CSF1R combination studies.
EZH2-SASP immune remodeling opens a new epigenetic immunotherapy axis. The University of Massachusetts data linking EZH2 to immune-cold PDAC phenotypes provide a mechanistic rationale for pairing PRC2 inhibitors with senescence-inducing regimens. IP in this space appears nascent, suggesting freedom-to-operate opportunities for early movers. PatSnap Analytics can identify white-space opportunities in epigenetic PDAC IP.
Wild-type KRAS PDAC (~5% of cases) represents an underserved but potentially more tractable precision subpopulation. Innocimab's nimotuzumab portfolio, with active patents in multiple jurisdictions, reflects a clinically-evidenced precision oncology strategy. Organizations focused on biomarker-driven patient selection should evaluate EGFR targeting in this subgroup. NCI genomic databases support KRAS wild-type subpopulation characterization.
Resistance pre-emption is becoming a design principle. Multiple filings in this dataset (UCB/MEK, Genentech/PDGFRα-STAT3, Astellas/multi-target combinations, Novartis/SHP2 + KRAS G12C) explicitly address adaptive resistance pathways. IP strategies that lock in combination partner claims early—before resistance mechanisms are widely understood—will be particularly valuable in PDAC's complex signaling landscape. Explore PatSnap customer case studies for real-world IP strategy examples.
Pancreatic Cancer Drug Pipeline Beyond KRAS — key questions answered
Several non-KRAS targets are prominently addressed across the dataset: CSF1R, GREM1, EZH2, EGFR (in wild-type KRAS/HRAS/NRAS PDAC), MEK, CDK4/6, PDGFRα/STAT3/S6, IL-33, CCR1, CD47/SIRPα, SOS1, and JNK1 are all flagged as actionable nodes, underscoring the multi-target nature of emerging PDAC strategies.
CSF1R blockade (cabiralizumab) depletes immunosuppressive tumor-associated macrophages (TAMs) from the pancreatic TME, reduces circulating CD14+CD16++ non-classical monocytes, and consequently upregulates PD-L1 expression, synergizing with PD-1 blockade to reinvigorate cytotoxic T cell responses. The Bristol-Myers Squibb CSF1R × PD-1 program references clinical trial NCT02526017.
GREM1 (Gremlin-1) is a BMP antagonist overexpressed in the PDAC stroma, where it confers chemoresistance. UCB Biopharma's patent portfolio describes GREM1 as a stromal driver of tumor progression and chemotherapy resistance, validated in KPC mouse models. Anti-GREM1 treatment combined with gemcitabine demonstrates significantly improved survival vs. vehicle controls in preclinical models.
EZH2 suppresses the pro-inflammatory senescence-associated secretory phenotype (SASP) in PDAC following therapy-induced senescence. EZH2 inhibition in combination with senescence-inducing therapies (MEK + CDK4/6 inhibitors) unleashes CCL2, CXCL9/10 chemokines and upregulates MHC-I and NK ligand expression, converting an immunologically cold tumor to an inflamed phenotype capable of innate immune engagement.
Multiple Innocimab patent jurisdictions reference a clinical study (Schultheis et al., Ann Oncol 2017) in which nimotuzumab + gemcitabine showed clinical benefit in patients with wild-type KRAS pancreatic cancer. Wild-type KRAS PDAC represents approximately 5% of cases and constitutes an underserved but potentially more tractable precision subpopulation.
MSKCC patent data describe an innate immune axis in PDAC where IL-33 drives ILC2 activation and subsequently CD8+ T cell engagement. Preclinical data report >70% cure rates in mouse models and ~40% reduction in tumor volume with rIL33 + anti-PD-1 in PD-1-resistant models, suggesting that innate lymphoid cell activation can bypass T cell exhaustion mechanisms.
Still have questions about the PDAC drug pipeline? Let PatSnap Eureka answer them for you.
Ask Eureka About PDAC TargetsAccelerate Your PDAC Drug Discovery Intelligence
Join 18,000+ innovators already using PatSnap Eureka to map the full pancreatic cancer patent landscape — from stromal targets to combination immune strategies.
References
- Combination of a gremlin-1 antagonist with a cytidine analogue or deoxycytidine analogue — UCB BIOPHARMA SRL, 2025, US [Patent]
- Combination of a gremlin-1 antagonist with a cytidine analogue or deoxycytidine analogue — UCB BIOPHARMA SRL, 2023, WO [Patent]
- Combination of a gremlin-1 antagonist with an inhibitor of ras-RAF-MEK-ERK signalling — UCB BIOPHARMA SRL, 2023, WO [Patent]
- Combination Anti-CSF1R and Anti-PD-1 Antibody Combination Therapy for Pancreatic Cancer — BRISTOL-MYERS SQUIBB COMPANY, 2021, US [Patent]
- Combination Anti-CSF1r and Anti-PD-1 antibody combination therapy for pancreatic cancer — BRISTOL-MYERS SQUIBB COMPANY, 2019, CA [Patent]
- EZH2 inhibition in pancreatic cancer — UNIVERSITY OF MASSACHUSETTS, 2023, WO [Patent]
- Combination therapy with MEK inhibitor and CDK4/6 inhibitor to treat pancreatic cancer — MEMORIAL SLOAN KETTERING CANCER CENTER, 2020, WO [Patent]
- Combination therapy for the treatment of pancreatic cancer — GENENTECH, INC, 2019, IL [Patent]
- Methods and compositions for treatment of pancreatic cancer — MEMORIAL SLOAN KETTERING CANCER CENTER, 2022, IL [Patent]
- Methods of using pharmacologic inhibitors of type 2 cytokine signaling to treat or prevent pancreatic cancer — MEMORIAL SLOAN KETTERING CANCER CENTER, 2021, US [Patent]
- Treatment and prognosis of pancreatic cancer (CCR1 antagonist) — Cambridge Enterprise Limited, 2022, CN [Patent]
- Compositions and methods for treatment of pancreatic cancer (ASO/aptamer) — American Microjet Technology LLC, 2025, CN [Patent]
- Treatment of patients diagnosed with PDAC using monoclonal antibodies against EGFR — INNOCIMAB PTE LTD, 2018, EP [Patent]
- Treatment of patients diagnosed with PDAC using monoclonal antibodies against EGFR — INNOCIMAB PTE LTD, 2017, WO [Patent]
- Methods for treatment of pancreatic cancer with anti-PD-L1, anti-TIGIT, gemcitabine and nab-paclitaxel — GENENTECH, INC., 2025, WO [Patent]
- c-Jun N-terminal kinase in pancreatic tumor stroma augments tumor development in mice — Department of Pancreatic Surgery, Huazhong University of Science and Technology, 2017 [Paper]
- National Cancer Institute — Pancreatic Cancer Information
- National Institutes of Health — ClinicalTrials.gov (NCT02526017 reference)
- World Intellectual Property Organization — International Patent Database
- European Patent Office — EP Patent Records (Innocimab EP active)
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report represents a snapshot of innovation signals within the retrieved dataset only and should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.